Clinical Trial Update: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition [Phase 3]

View source ↗

Summary

Phase 3 trial of crovalimab in paroxysmal nocturnal hemoglobinuria patients not previously treated with complement inhibition; results of the study have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Crovalimab (crovalimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-05